Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 2/20 | 0.73 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | PPARD | Q03181 | 3/20 | 0.32 |
| ▸ | PPARA | Q07869 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.30 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229168 | 0.84 | VDR (1.00) | VDRPPARGPPARDPPARANPC1 | |
| SCHEMBL6477633 | 0.84 | VDR (0.67) | VDR | |
| SCHEMBL6472936 | 0.83 | VDR (0.68) | VDRMAPTL3MBTL1 | |
| SCHEMBL4888601 | 0.82 | VDR (0.92) | VDRPPARGPPARDPPARANPC1 | |
| SCHEMBL4617119 | 0.79 | VDR (0.75) | VDR | |
| SCHEMBL2890000 | 0.78 | VDR (0.66) | VDRPPARGPPARDPPARA | |
| SCHEMBL2854911 | 0.78 | VDR (0.88) | VDR | |
| SCHEMBL2641441 | 0.78 | VDR (0.84) | VDRPPARGPPARDPPARANPC1 | |
| SCHEMBL1074550 | 0.78 | VDR (0.74) | VDRPPARGMEN1NPC1ALDH1A1 | |
| SCHEMBL1022006 | 0.78 | VDR (0.61) | VDRMEN1NPC1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286285-A1 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286285-A1 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state | CYP24A1, VDR, CYP2R1 | VDR 2/4885PPARG 83/4885PPARD 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.